Erector Spinae Plane Block in Post-herpetic Neuralgia
Postherpetic Neuralgia
About this trial
This is an interventional supportive care trial for Postherpetic Neuralgia focused on measuring Herpes Zoster, Postherpetic neuralgia, Erector spina plane block
Eligibility Criteria
Inclusion Criteria:
- Cases presenting to the Pain Clinic with acute pain due to postherpetic neuralgia in thoracic and/or lumbar dermatomes with a numerical rating scale (NRS) of 6 or more.
Exclusion Criteria:
- Patients commenced on opioids for any other reason rather than postherpetic neuralgia
- Secondary bacterial infection at the site of injection
- Uncontrolled psychiatric illness
- Uncooperative patients
- Refusal to participate in the study
- Diagnosed or suspected coagulopathy
- Morbid Obese patients with BMI >50 kg/m2
- Known history of allergy to local anesthetics
- Platelet count less than 75,000/ cc
Sites / Locations
- Tanta University hospitals
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Experimental
Experimental
Group A
Group B
Group C
Patients will be subjected to the routine medical treatment of post herpetic neuralgia as controls (Pregabalin, acyclovir, and paracetamol) and sham erector spinae plane block
Patients will be subjected to erector spinae block by bupivacaine (2 - 2.5 mg/kg, with a maximum of 175 mg/dose) together with medical treatment.
Patients that will be subjected to erector spinae block by bupivacaine (2 - 2.5 mg/kg, with a maximum of 175 mg/dose with the addition of MgSO4 (equivalent to 100 mg)) together with medical treatment.